Rinvoq (Upadacitinib) Patent Expiration, LOE Window & CMS Spending

Rinvoq (Upadacitinib) by AbbVie: FDA Orange Book core substance LOE 2036-10-17 (last listed 2038-03-09), 0 AB generics, $1.98B 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN211675 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-10-17
Last Listed Patent or Exclusivity Date2038-03-09
Orange Book Patents (*PED Extensions)45 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.98B
2024 Medicare Part D Spend$1.39B
2024 Medicaid Spend$592.5M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 24.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.